SMMT — Recent News Coverage
All news mentioning SMMT in ESEN's AI-graded feed
News stories with SMMT as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on SMMT. See /coverage/SMMT for the 30-day aggregate.
GURUFOCUS.COM
·
2026-10-25
HIGH
BULLISH
CORR0.72
Summit Therapeutics' Ivonescimab Shows Survival Benefit in Biliary Tract Cancer, SMMT Stock Reacts
$SMMT
◈ ESEN AI
SMMT disclosed positive Phase 3 trial results for ivonescimab in biliary tract cancer, demonstrating a survival benefit that represents a material clinical validation event. This outcome constitutes a pivotal catalyst f…
SEEKINGALPHA.COM
·
2026-07-24
NEUTRAL
NEUTRAL
CORR0.35
Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript
$SMMT
◈ ESEN AI
Summit Therapeutics (SMMT) reported Q2 2026 earnings via earnings call on July 23, 2026. The earnings call transcript itself provides limited sentiment without detailed financial metrics or guidance commentary. Earnings…
SEEKINGALPHA.COM
·
2026-07-23
NEUTRAL
NEUTRAL
CORR0.35
Summit Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:SMMT) 2026-07-23
$SMMT
◈ ESEN AI
Summit Therapeutics (SMMT) released its Q2 2026 earnings presentation, a routine disclosure event typical for biotech firms. The publication of earnings slides without accompanying narrative detail or headline metrics s…
FINANCE.YAHOO.COM
·
2026-06-22
NEUTRAL
BEARISH
CORR0.35
Summit Therapeutics (SMMT): A $500 Million Stock Offering Pulled Just One Day After Filing
$SMMT
◈ ESEN AI
Summit Therapeutics (SMMT) withdrew a planned $500 million equity offering after just 24 hours, citing unfavorable market conditions. This abrupt pullback signals either deteriorating investor appetite for the specific …
SEEKINGALPHA.COM
·
2026-06-22
NEUTRAL
NEUTRAL
CORR0.35
Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet (NASDAQ:SMMT)
$SMMT
◈ ESEN AI
Summit Therapeutics (SMMT) represents a classic biotech profile characterized by high volatility and event-driven trading dynamics. The company's stock performance hinges on binary outcomes tied to clinical trial result…
SEEKINGALPHA.COM
·
2026-06-15
NEUTRAL
NEUTRAL
CORR0.25
Summit Therapeutics: Getting A Foot In The Door Isn't Getting Through It (NASDAQ:SMMT)
$SMMT
◈ ESEN AI
Summit Therapeutics (SMMT) has achieved a regulatory milestone with BLA (Biologics License Application) acceptance for ivonescimab in second-line EGFR-mutant non-small-cell lung cancer (NSCLC). This represents forward p…
EXPLORE OTHER FILTERS